Wilms' tumor gene 1 (WT1) in endometrial carcinoma

Gynecologic Oncology

Volumn 111, Issue 3, 2008, Pages 502-508

  Coosemans, An ^a   Moerman, Philippe ^a   Verbist, Godelieve ^a   Maes, Wim ^a   Neven, Patrick ^a   Vergote, Ignace ^a   Van Gool, Stefaan W ^a   Amant, Frédéric ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Endometrial cancer; Tumor; Uterus; Wilms' tumor gene 1 (WT1)

Indexed keywords

ADULT; AGED; ARTICLE; CELL HETEROGENEITY; CLINICAL ARTICLE; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GENE; UTERUS CANCER; WT1 GENE;

ADENOCARCINOMA, CLEAR CELL; AGED; BIOPSY; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, WILMS TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM STAGING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; WT1 PROTEINS;

EID: 56449117529     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.08.032     Document Type: Article

References (30)

1. Hohenstein P., and Hastie N.D. The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet 15 Spec No 2 (2006) R196-R201
2. Herzer U., Crocoll A., Barton D., Howells N., and Englert C. The Wilms tumor suppressor gene wt1 is required for development of the spleen. Curr Biol 9 15 (1999) 837-840
3. Kreidberg J.A., Sariola H., Loring J.M., Maeda M., Pelletier J., Housman D., et al. WT-1 is required for early kidney development. Cell 74 4 (1993) 679-691
4. Moore A.W., Schedl A., McInnes L., Doyle M., Hecksher-Sorensen J., and Hastie N.D. YAC transgenic analysis reveals Wilms' tumour 1 gene activity in the proliferating coelomic epithelium, developing diaphragm and limb. Mech Dev 79 1-2 (1998) 169-184
5. Moore A.W., McInnes L., Kreidberg J., Hastie N.D., and Schedl A. YAC complementation shows a requirement for Wt1 in the development of epicardium, adrenal gland and throughout nephrogenesis. Development 126 9 (1999) 1845-1857
6. Nakatsuka S., Oji Y., Horiuchi T., Kanda T., Kitagawa M., Takeuchi T., et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 19 6 (2006) 804-814
7. Amant F., Moerman P., Neven P., Timmerman D., Van Limbergen E., and Vergote I. Endometrial cancer. Lancet 366 9484 (2005) 491-505
8. Iiyama T., Udaka K., Takeda S., Takeuchi T., Adachi Y.C., Ohtsuki Y., et al. WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol 51 5 (2007) 519-530
9. Mailander V., Scheibenbogen C., Thiel E., Letsch A., Blau I.W., and Keilholz U. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 18 1 (2004) 165-166
10. Oka Y., Tsuboi A., Taguchi T., Osaki T., Kyo T., Nakajima H., et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 101 38 (2004) 13885-13890
11. Oka Y., Tsuboi A., Elisseeva O.A., Nakajima H., Fujiki F., Kawakami M., et al. WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers. Sci World J 7 (2007) 649-665
12. Van Driessche A., Gao L., Stauss H.J., Ponsaerts P., Van Bockstaele D.R., Berneman Z.N., et al. Antigen-specific cellular immunotherapy of leukemia. Leukemia 19 11 (2005) 1863-1871
13. Izumoto S., Tsuboi A., Oka Y., Suzuki T., Hashiba T., Kagawa N., et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 108 (2008) 963-971
14. Coosemans A., Nik S.A., Caluwaerts S., Lambin S., Verbist G., Van Bree R., et al. Upregulation of Wilms' tumour gene 1 (WT1) in uterine sarcomas. Eur J Cancer 43 10 (2007) 1630-1637
15. Acs G., Pasha T., and Zhang P.J. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol 23 2 (2004) 110-118
16. Al Hussaini M., Stockman A., Foster H., and McCluggage W.G. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 44 2 (2004) 109-115
17. Dupont J., Wang X., Marshall D.S., Leitao M., Hedvat C.V., Hummer A., et al. Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray. Gynecol Oncol 94 2 (2004) 449-455
18. Egan J.A., Ionescu M.C., Eapen E., Jones J.G., and Marshall D.S. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium. Int J Gynecol Pathol 23 2 (2004) 119-122
19. Euscher E.D., Malpica A., Deavers M.T., and Silva E.G. Differential expression of WT-1 in serous carcinomas in the peritoneum with or without associated serous carcinoma in endometrial polyps. Am J Surg Pathol 29 8 (2005) 1074-1078
20. Goldstein N.S., and Uzieblo A. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol 117 4 (2002) 541-545
21. Hashi A., Yuminamochi T., Murata S., Iwamoto H., Honda T., and Hoshi K. Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum. Int J Gynecol Pathol 22 4 (2003) 374-377
22. Kiyokawa T., Kanetsuna Y., Harada T., Sasaki M., Suzuki M., and Kawakami M. WT-1 expression in ovarian epithelial tumors and endometrial serous carcinoma. Mod Pathol 16 A837 (2003) Ref Type: Abstract
23. Shevchuk M.M., Lallas T.A., and DaSilva M. Endometrial carcinoma: do oncogene studies separate types I and II. Mod Pathol 16 A216 (2003) Ref Type: Abstract
24. Zhang Q., Wright T., Alexis D., and Mansukhani M. Differential expression of WT1 in uterine serous and endometrioid carcinoma. Mod Pathol 16 A988 (2003) Ref Type: Abstract
25. Heatley M.K. WT-1 in ovarian and endometrioid serous carcinoma: a meta-analysis. Histopathology 46 4 (2005) 468
26. Goldstein N.S. WT-staining in endometrial serous carcinomas. Int J Gynecol Pathol 23 4 (2004) 405-407
27. Rackley R., Casey G., Zhao X.L., Miller D.W., Williams B.R., and Coppes M.J. Analysis of the Wilms tumor suppressor gene WT1 in endometrial carcinoma. Genes, Chromosomes Cancer 14 4 (1995) 313-315
28. Niksic M., Slight J., Sanford J.R., Caceres J.F., and Hastie N.D. The Wilms' tumour protein (WT1) shuttles between nucleus and cytoplasm and is present in functional polysomes. Hum Mol Genet 13 4 (2004) 463-471
29. Wagner N., Michiels J.F., Schedl A., and Wagner K.D. The Wilms' tumour suppressor WT1 is involved in endothelial cell proliferation and migration: expression in tumour vessels in vivo. Oncogene 27 (2008) 3662-3672
30. Hunder N., Wallen H., Cao J., Hendricks D., Reilly J., Rodmyre R., et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358 (2008) 2698-2703